178 results on '"Hochmair, M.J."'
Search Results
2. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
3. 121P MK-7684A (vibostolimab [vibo] plus pembrolizumab [pembro] coformulation) with/without docetaxel in metastatic NSCLC after platinum-chemotherapy (chemo) and immunotherapy
4. 91P Treatment (tx) patterns and outcomes in resectable early-stage non-small cell lung cancer (NSCLC): A global real-world (rw) study
5. PP01.31 Real-World Treatment Outcomes of Amivantamab in Pre-Approval Access (PAA) Participants with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations (ex20ins)
6. PP01.40 Target Lesion Response and Outcomes in Patients Treated with Brigatinib vs Crizotinib in ALTA-1L
7. 55P Comparison of BiomeOne and PD-L1 expression tests as a predictor for response to immune checkpoint inhibitors (ICI) in patients with non-small cell lung cancer (NSCLC)
8. EP08.02-122 Real-world Experience with Capmatinib in MET Exon 14-mutated Non-small Cell Lung Cancer (RECAP)
9. 1530P Durvalumab (D) + platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN
10. 973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC
11. 1051P Radiotherapy (RT) and efficacy of immune checkpoint inhibitors (ICI), chemotherapy (CTx) and chemoimmunotherapy (CIT) in patients with non-small cell lung cancer (NSCLC)
12. EP02.01-008 Clinicopathological Features of Rare but Targetable Mutations in Surgically Resected Lung Carcinomas
13. 117P BiomeOne: Multi-centric validation of a novel microbiome-based biomarker to predict response to cancer immunotherapy
14. 141O Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study
15. 29P Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results
16. 35P Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins)
17. Rare case of chemotherapy-refractory metastatic vaginal squamous cell carcinoma with complete response to concurrent pembrolizumab and radiotherapy- case report and literature review
18. P51.05 Sequential Afatinib and Osimertinib in Patients With Advanced EGFRm+ NSCLC and Acquired T790M: The Real-World UpSwinG study
19. VP5-2021: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo)
20. 1223P Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm+) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG)
21. 1279P The prognostic value of chemotherapy-induced neutropenia (CIN) in patients with advanced non-small cell lung cancer (NSCLC) in the era of chemoimmunotherapy (CIT)
22. 1195P Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI–naive ALK+ NSCLC: Final results from ALTA-1L
23. 1206P UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in first-liNe setting (UNICORN)
24. LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study
25. FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189
26. P48.03 First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN
27. 38P Matching-adjusted indirect comparison (MAIC) of treatment outcomes for selective RET inhibitors, selpercatinib and pralsetinib, in non-small cell lung cancer (NSCLC)
28. 400P Sequential afatinib and osimertinib in real-world EGFR mutation positive (EGFRm+) NSCLC: Final analysis of Asian patients in the GioTag study
29. 379MO Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN
30. 1304P Brigatinib (BRG) vs crizotinib (CRZ) in Asian vs non-Asian patients (pts): Update from ALTA-1L
31. 1300P Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ): Updated results from the ALTA-1L trial
32. 1781MO IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer
33. 1299P Real-world treatment patterns, clinical outcomes and EGFR/T790M testing practices in patients with EGFRm advanced NSCLC and 1L EGFR TKI therapy: A retrospective multinational study (REFLECT)
34. LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN
35. 1350P Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC)
36. LBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN
37. O.03 KEYNOTE-189: OS Update and Progression After the Next Line of Therapy (PFS2) with Pembrolizumab + Chemotherapy for Metastatic Nonsquamous NSCLC
38. OA03.09 Overall Survival in Patients with EGFRM+ NSCLC Receiving Sequential Afatinib and Osimertinib: an Update of the Giotag Study
39. Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia
40. Mutation tracking in circulating tumour DNA predicts relapse in completely resected EGFR-mutated NSCLC
41. Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
42. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial
43. Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
44. PD2.05 Overall Survival in Pts with EGFRm+ NSCLC Receiving Sequential Afatinib and Osimertinib: Updated Analysis of the GioTag Study
45. PD2.02 Pembrolizumab plus Pemetrexed-Platinum for Patients with Metastatic Nonsquamous NSCLC and Liver or Brain Metastases: Results from KEYNOTE-189
46. Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase II ALTA trial
47. Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm+) advanced NSCLC: Updated data from the GioTag real-world study
48. P1.01-118 Overall Survival in Pts with EGFRm+ NSCLC Receiving Sequential Afatinib and Osimertinib: Updated Analysis of the GioTag Study
49. PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN
50. Analysis of circulating tumour DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.